EDAP TMS S.A. (EDAP) 株式分析

企業概要

EDAP TMS S.A. engages in the development, manufacturing, promotion, and distribution of minimally-invasive medical devices specifically designed for urology applications that utilize proprietary ultrasound technology. This business model operates within the Healthcare sector, specifically targeting the Medical Distribution industry, which implies a reliance on B2B relationships with medical facilities and hospitals rather than direct-to-consumer sales. The company currently maintains a market capitalization of $125.94M and generates annual revenue of $70.53M, while specific employee count data is unavailable in the provided records. These valuation and revenue figures indicate that EDAP operates as a mid-cap entity with a significant revenue base relative to its market valuation, suggesting a mature operational footprint in the international medical device market spanning Asia, France, the United States, and other global regions.

財務健全性

The company reported a trailing twelve-month revenue of $70.53M, yet this generated a net income of -$29,246,000, revealing a substantial cost structure where expenses significantly exceed operating profits before interest and taxes. The EBITDA stands at -$21,288,000, indicating that the core operating business is currently generating negative cash flows from operations before non-cash expenses like depreciation and amortization. Free cash flow is reported at -$12,130,500, which signifies a lack of financial flexibility as the company is burning cash rather than generating liquidity to fund operations or reduce leverage. The gross margin stands at 42.5%, which reflects a healthy pricing power or cost advantage in manufacturing medical devices, yet this is offset by an operating margin of -26.2% and a profit margin of -41.5%. These negative operating and profit margins indicate that high overhead costs, likely related to research, development, or distribution networks, are consuming the gross profits generated from sales. Regarding liquidity and leverage, the company holds $20.45M in cash against $27.75M in total debt, resulting in a debt-to-equity ratio of 142.93, which characterizes a highly leveraged balance sheet with more debt than equity. The current ratio of 1.54 suggests that the company possesses adequate short-term assets to cover its short-term liabilities, though the negative earnings pressure complicates long-term solvency. Return on Equity is -94.5% and Return on Assets is -18.3%, metrics that clearly demonstrate that management effectiveness is currently negative as the company destroys shareholder value and utilizes assets inefficiently to generate profit.

バリュエーション評価

The valuation metrics present a complex picture with a trailing P/E ratio of N/A due to losses, while the forward P/E stands at -5.79, implying that future earnings expectations remain negative or that the market is pricing in significant uncertainty regarding an earnings turnaround. The price-to-book ratio is 6.49, indicating that the market values the company at a substantial premium over its tangible book value, which is often observed in technology or intellectual property-heavy sectors despite current losses. The price-to-sales ratio of 1.79 and an EV/EBITDA of -6.26 suggest that investors are willing to pay nearly twice the revenue for the company, a multiple that typically applies to growth stocks but is unusually high for a firm with negative EBITDA. The stock price has ranged between a 52-week low of $1.21 and a 52-week high of $5.05, placing the current trading price at a level that reflects recent volatility and potential downside from the highs. The beta of -0.08 is an anomalous metric that suggests the stock price moves counter to the broader market or exhibits negligible correlation, which could indicate extreme idiosyncratic risk or data irregularities in the calculation.

Growth & Income

Revenue growth year-over-year is -19.0%, while earnings growth is N/A due to the absence of comparable positive earnings in the prior period, indicating that the company is contracting rather than expanding its top line. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains all earnings, though these earnings are currently negative. Consequently, the company is not reinvesting earnings into growth in the traditional sense of funding expansion from profits, but rather must seek external financing or utilize cash reserves to sustain operations during this contractionary phase. The overall growth and income profile is characterized by significant revenue decline, negative profitability, and an absence of dividend income, presenting a challenging investment case focused entirely on operational turnaround rather than value accretion or income generation.